CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 3, 2010, Pages 861-871

  Motawaj, Mouhammad ^a   Peoc'H, Katell ^b,c   Callebert, Jacques ^b,c   Arrang, Jean Michel ^a  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Alzheimer's disease; cerebrospinal fluid; cognitive deficits; histaminergic system activity; mast cells; microglia; neuroinflammation; neurons; tele methylhistamine

Indexed keywords

HISTAMINE; TELE METHYLHISTAMINE;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; FEMALE; HISTAMINE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; SENESCENCE; SEX RATIO;

EID: 78650646498     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100381     Document Type: Article

References (98)

1. Haas H, Panula P (2003) The role of histamine and the tubero- mamillary nucleus in the nervous system. Nat Rev Neurosci 4, 121-130.
2. Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88, 1183-1241.
3. Passani MB, Lin JS, Hancock A, Crochet S, Blandina P (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25, 618625.
4. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, Stark H, Elz S, Schunack W, Schwartz J (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3 -receptor antagonist. J Pharmacol Exp Ther 287, 658-666.
5. Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB (2007) Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 73, 1123-1134.
6. Medhurst AD, Briggs MA, Bruton G, Calver AR, Chessell I, Crook B, Davis JB, Davis RP, Foley AG, Heslop T, Hirst WD, Medhurst SJ, Ociepka S, Ray A, Regan CM, Sargent B, Schog- ger J, Stean TO, Trail BK, Upton N, White T, Orlek B, Wilson DM (2007) Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine- induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem Pharmacol 73, 1182-1194.
7. Miyazaki S, Imaizumi M, Onodera K (1995) Effects of thioperamide, a histamine H3-receptor antagonist, on a scopolamine-induced learning deficit using an elevated plus- maze test in mice. Life Sci 57, 2137-2144.
8. Meguro K, Yanai K, Sakai N, Sakurai E, Maeyama K, Sasaki H, Watanabe T (1995) Effects of thioperamide, a histamine H3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol Biochem Behav 50, 321-325.
9. Komater VA, Buckley MJ, Browman KE, Pan JB, Hancock AA, Decker MW, Fox GB (2005) Effects of histamine H3 receptor antagonists in two models of spatial learning. Behav Brain Res 159, 295-300.
10. Morisset S, Traiffort E, Schwartz JC (1996) Inhibition of his- tamine versus acetylcholine metabolism as a mechanism of tacrine activity. Eur J Pharmacol 315, R1-2.
11. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel- Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM (2000) High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408, 860-864.
12. Leurs R, Bakker RA, Timmerman H, de Esch IJ (2005) The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4, 107-120.
13. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cow- art MD, Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154, 1166-1181.
14. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ (2005) Histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 10, 1613-1627.
15. Engelborghs S, De Deyn PP (1997) The neurochemistry of Alzheimer's disease. Acta Neurol Belg 97, 67-84.
16. Schmitt HP (2005) Neuro-modulation, aminergic neuro- disinhibition and neuro-degeneration. Draft of a comprehensive theory for Alzheimer disease. Med Hypotheses 65, 1106-1119.
17. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24, 1-23.
18. Airaksinen MS, Paetau A, Paljarvi L, Reinikainen K, Riekki- nen P, Suomalainen R, Panula P (1991) Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 44, 465-481.
19. Airaksinen MS, Reinikainen K, Riekkinen P, Panula P (1991) Neurofibrillary tangles and histamine-containing neurons in Alzheimer hypothalamus. Agents Actions 33, 104-107.
20. Nakamura S, Takemura M, Ohnishi K, Suenaga T, Nishimura M, Akiguchi I, Kimura J, Kimura T (1993) Loss oflarge neurons and occurrence of neurofibrillary tangles in the tubero- mammillary nucleus of patients with Alzheimer's disease. NeurosciLett 151, 196-199.
21. Saper CB, German DC (1987) Hypothalamic pathology in Alzheimer's disease. Neurosci Lett 74, 364-370.
22. Simpson J, Yates CM, Watts AG, Fink G (1988) Congo red birefringent structures in the hypothalamus in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 14, 381393.
23. Swaab DF, Hofman MA, Lucassen PJ, Purba JS, Raadsheer FC, Van de Nes JA (1993) Functional neuroanatomy and neuropathology of the human hypothalamus. AnatEmbryol (Berl) 187, 317-330.
24. van de Nes JA, Kamphorst W, Ravid R, Swaab DF (1993) The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer's disease patients. Brain 116, 103-115.
25. Ishunina TA, van Heerikhuize JJ, Ravid R, Swaab DF (2003) Estrogen receptors and metabolic activity in the human tubero mamillary nucleus: changes in relation to sex, aging and Alzheimer's disease. Brain Res 988, 84-96.
26. Salehi A, Heyn S, Gonatas NK, Swaab DF (1995) Decreased protein synthetic activity ofthe hypothalamic tuberomamillary nucleus in Alzheimer's disease as suggested by smaller Golgi apparatus. Neurosci Lett 193, 29-32.
27. Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki H (2000) Histamine Hi receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99, 721-729.
28. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, Relja M (1998) Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82, 993-997.
29. Mazurkiewicz-Kwilecki IM, Nsonwah S (1989) Changes in the regional brain histamine and histidine levels in postmortem brains of Alzheimer patients. Can J Physiol Pharmacol 67, 75-78.
30. Schneider C, Risser D, Kirchner L, Kitzmuller E, Cairns N, Prast H, Singewald N, Lubec G (1997) Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. Neurosci Lett 222, 183-186.
31. Cacabelos R, Yamatodani A, Niigawa H, Hariguchi S, Ta- da K, Nishimura T, Wada H, Brandeis L, Pearson J (1989) Brain histamine in Alzheimer's disease. Methods Find Exp Clin Pharmacol 11, 353-60.
32. Niimi M, Mochizuki T, Cacabelos R, Yamatodani A (1993) Increase of histidine decarboxylase activity in mice hy- pothalamus after intracerebroventricular administration of lipopolysaccharide. Methods Find Exp Clin Pharmacol 15, 509-514.
33. Niimi M, Yamamoto Y, Takemori H, Uno A, Kondo Y, Yam- atodani A (1997) Lipopolysaccharide and interleukin-1beta augmented histidine decarboxylase activity in cultured cells of the rat embryonic brain. J Neurochem 69, 851-858.
34. Katoh Y, Niimi M, Yamamoto Y, Kawamura T, Morimoto- Ishizuka T, Sawada M, Takemori H, Yamatodani A (2001) His- tamine production by cultured microglial cells of the mouse. Neurosci Lett 305, 181-184.
35. Beal MF, Growdon JH (1986) CSF neurotransmitter markers in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 10, 259-270.
36. Sjogren M, Wikkelso C, Ostling S, Wallin A, Blennow K (2002) Biological correlates of clinical subgroups of Alzheimer's disease. Dement Geriatr Cogn Disord 14, 191-197.
37. Prell GD, Khandelwal JK, Burns RS, LeWitt PA, Green JP (1991) Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Arch Gerontol Geriatr 12, 1-12.
38. Garbarg M, TuongMD, Gros C, Schwartz JC (1989) Effects of histamine H3-receptor ligands on various biochemical indices of histaminergic neuron activity in rat brain. Eur J Pharmacol 164, 1-11.
39. Prell GD, Green JP (1994) Measurement of histamine metabolites in brain and cerebrospinal fluid provides insights into histaminergic activity. Agents Actions 41, C5-8.
40. Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Mor- rishow AM, Kirch DG, Linnoila M, Wyatt RJ (1995) His- tamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14, 93-104.
41. Kiviranta T, Tuomisto L, Airaksinen EM (1994) Diurnal and age-related changes in cerebrospinal fluid tele- methylhistamine levels during infancy and childhood. Pharmacol Biochem Behav 49, 997-1000.
42. Garbarg M, Pollard H, Trung Tuong MD, Schwartz JC, Gros C (1989) Sensitive radioimmunoassays for histamine and tele- methylhistamine in the brain. J Neurochem 53, 1724-1730.
43. Garbarg M, Arrang JM, Rouleau A, Ligneau X, Tuong MD, Schwartz JC, Ganellin CR (1992) S-[2-(4- imidazolyl)ethyl]isothiourea, a highly specific and potent his- tamine H3 receptor agonist. J Pharmacol Exp Ther 263, 304-310.
44. Khandelwal JK, Hough LB, Morrishow AM, Green JP (1982) Measurement of tele-methylhistamine and histamine in human cerebrospinal fluid, urine, and plasma. Agents Actions 12, 583590.
45. Prell GD, Khandelwal JK, Burns RS, LeWitt PA, Green JP (1988) Elevated levels of histamine metabolites in cere- brospinal fluid ofaging, healthy humans. Compr Gerontol [A] 2, 114-119.
46. Arrang JM (2007) Histamine and schizophrenia. Int Rev Neu- robiol 78, 247-287.
47. Oishi R, Nishibori M, Itoh Y, Saeki K (1986) Diazepam- induced decrease in histamine turnover in mouse brain. Eur J Pharmacol 124, 337-342.
48. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M (2002) The sedative component of anesthesia is mediated by GABAa receptors in an endogenous sleep pathway. NatNeu- rosci 5, 979-984.
49. Cumming P, Reiner PB, Vincent SR (1990) Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4- tetrahydroacridine (THA). Biochem Pharmacol 40, 1345-1350.
50. Taraschenko OD, Barnes WG, Herrick-Davis K, Yokoyama Y, Boyd DL, Hough LB (2005) Actions of tacrine and galan- thamine on histamine-N-methyltransferase. Meth Find Exp Clin Pharmacol 27, 161-165.
51. Fekete CS, Strutton PH, Cagampang FR, Hrabovszky E, Kallo I, Shughrue PJ, Dobo E, Mihaly E, Baranyi L, Okada H, Pan- ula P, Merchenthaler I, Coen CW, Liposits ZS (1999) Estrogen receptor immunoreactivity is present in the majority of central histaminergic neurons: evidence for a new neu- roendocrine pathway associated with luteinizing hormone- releasing hormone-synthesizing neurons in rats and humans. Endocrinology 140, 4335-4341.
52. Faucard R, Armand V, Heron A, Cochois V, Schwartz JC, Ar- rang JM (2006) N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem 98, 1487-1496.
53. Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, Steed M (2000) Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR Am JNeuroradiol 21, 1857-1868.
54. Ishunina TA, Kamphorst W, Swaab DF (2004) Metabolic alterations in the hypothalamus and basal forebrain in vascular dementia. JNeuropathol Exp Neurol 63, 1243-1254.
55. Blennow K, Wallin A, Gottfries CG, Lekman A, Karlsson I, Skoog I, Svennerholm L (1992) Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiol Aging 13, 107-113.
56. Parnetti L, Gaiti A, Reboldi GP, Santucci C, Mecocci P, Brunetti M, Cadini D, Senin U (1992) CSF monoamine metabolites in old age dementias. Mol Chem Neuropathol 16, 143-157.
57. Nyback H, Nyman H, Blomqvist G, Sjogren I, Stone-Elander S (1991) Brain metabolism in Alzheimer's dementia: studies ofiiC-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiatry 54, 672-678.
58. Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T (1991) CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 29, 1110-1118.
59. Sheline YI, Miller K, Bardgett ME, Csernansky JG (1998) Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction. Am J Geriatr Psychiatry 6, 155-161.
60. Raskind MA, Peskind ER, Holmes C, Goldstein DS (1999) Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 46, 756-765.
61. Hoogendijk WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W, Eikelenboom P, Swaab DF (1999) Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 45, 82-91.
62. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2006) Compensatory changes in the noradrener- gic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 26, 467-478.
63. Town T (2010) Inflammation, immunity, and Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 129-131.
64. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6, 193-201.
65. Lue LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer's disease. MolNeurobiol 41, 115-128.
66. Graeber MB, Streit WJ (2010) Microglia: biology and pathology. Acta Neuropathol 119, 89-105.
67. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37, 503-509.
68. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9, 429-439.
69. Godbout JP, Johnson RW (2009) Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am 29, 321-337.
70. Luo XG, Ding JQ, Chen SD (2010) Microglia in the aging brain: relevance to neurodegeneration. Mol Neurodegener 5, 12.
71. Sparkman NL, Johnson RW (2008) Neuroinflammation associated with aging sensitizes the brain to the effects ofinfection or stress. Neuroimmunomodulation 15, 323-30.
72. Niederhoffer N, Levy R, Sick E, Andre P, Coupin G, Lombard Y, Gies JP (2009) Amyloid beta peptides trigger CD47- dependent mast cell secretory and phagocytic responses. Int J Immunopathol Pharmacol 22, 473-483.
73. Skaper SD, Facci L, Romanello S, Leon A (1996) Mast cell activation causes delayed neurodegeneration in mixed hip- pocampal cultures via the nitric oxide pathway. J Neurochem 66, 1157-1166.
74. Cacabelos R, Fernandez-Novoa L, Perez-Trullen JM, Franco- Maside A, Alvarez XA (1992) Serum histamine in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 14, 711-715.
75. Fernandez-Novoa L, Cacabelos R (2001) Histamine function in brain disorders. Behav Brain Res 124, 213-233.
76. Alvarez XA, Fernandez-Novoa L, Caamano J, Corzo L, Zas R, Beyer K, Lao JI, Cacabelos R (1997) Cerebrovascular changes associated with interleukin-1 beta (IL-1 beta) and histamine levels in Alzheimer's disease. Ann N Y Acad Sci 826, 375-378.
77. Teuscher C, Subramanian M, Noubade R, Gao JF, Offner H, Zachary JF, Blankenhorn EP (2007) Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci U SA 104, 10146-10151.
78. Beghdadi W, Porcherie A, Schneider BS, Morisset S, Dubayle D, Peronet R, Dy M, Louis J, Arrang JM, Mecheri S (2009) Histamine H3 receptor-mediated signaling protects mice from cerebral malaria. PLoS One 4, e6004.
79. Silverman AJ, Sutherland AK, Wilhelm M, Silver R (2000) Mast cells migrate from blood to brain. J Neurosci 20, 401-408.
80. Zhang M, Thurmond RL, Dunford PJ (2007) The histamine H4 receptor: A novel modulator of inflammatory and immune disorders. Pharmacol Ther 113, 594-606.
81. Tanaka S, Ichikawa A (2006) Recent advances in molecular pharmacology of the histamine systems: immune regulatory roles of histamine produced by leukocytes. J Pharmacol Sci 101, 19-23.
82. Jutel M, Blaser K, Akdis CA (2006) The role of histamine in regulation of immune responses. Chem Immunol Allergy 91, 174-187.
83. Gaykema RP, Park SM, McKibbin CR, Goehler LE (2008) Lipopolysaccharide suppresses activation of the tuberomam- millary histaminergic system concomitant with behavior: a novel target of immune-sensory pathways. Neuroscience 152, 273-287.
84. Niimi M, Mochizuki T, Yamamoto Y, Yamatodani A (1994) Interleukin-1 beta induces histamine release in the rat hypothalamus in vivo. Neurosci Lett 181, 87-90.
85. Knigge U, Kjaer A, Jorgensen H, Garbarg M, Ross C, Rouleau A, Warberg J (1994) Role of hypothalamic histaminergic neurons in mediation of ACTH and beta-endorphin responses to LPS endotoxin in vivo. Neuroendocrinology 60, 243-251.
86. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP (2010) Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107, 6058-6063.
87. Huang M, Pang X, Letourneau R, Boucher W, Theoharides TC (2002) Acute stress induces cardiac mast cell activation and histamine release, effects that are increased in Apolipoprotein E knockout mice. Cardiovasc Res 55, 150-160.
88. Mace BE, Wang H, Lynch JR, Moss J, Sullivan P, Colton H, Morgan K, Renauld JC, Laskowitz DT (2007) Apolipopro- tein E modifies the CNS response to injury via a histamine- mediated pathway. Neurol Res 29, 243-250.
89. Bongers G, Leurs R, Robertson J, Raber J (2004) Role of H3-receptor-mediated signaling in anxiety and cognition in wild-type and Apoe-/- mice. Neuropsychopharmacology 29, 441-449.
90. van Meer P, Pfankuch T, Raber J (2007) Reduced histamine levels and H3 receptor antagonist-induced histamine release in the amygdala of Apoe-/- mice. J Neurochem 103, 124-130.
91. Arrang JM, Morisset S, Gbahou F (2007) Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 28, 350-357.
92. Hancock AA, Brune ME (2005) Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 14, 223-241.
93. Esbenshade TA, Fox GB, Cowart MD (2006) Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv 6, 77-88.
94. Tokita S, Takahashi K, Kotani H (2006) Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci 101, 12-18.
95. Hancock AA (2006) The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of his- tamine H3 antagonists/inverse agonists. Biochem Pharmacol 71, 1103-1113.
96. Hancock AA, Fox GB (2004) Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 13(10), 1237-1248.
97. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Wool- ley ML, Worby A, Wilson DM (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321, 1032-1045.
98. Medhurst AD, Roberts JC, Lee J, Chen CP, Brown SH, Roman S, Lai MK (2009) Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 157, 130-138.